Versanis, With $70m Series A, To Advance Abandoned Novartis Drug In Obesity

 
• By Joseph Haas
Hand holds the magnifying glass in front of an open notebook. Among the many icons, attention is focused on the money icon. Financial operations, banking, lending, etc.
With $70m in series A cash, Versanis hopes to develop obesity drug to take on semaglutide

More from Strategy

More from Business